The current syndicate of institutional investors all participated in the financing.
The proceeds will be used to support the company’s expanding commercialization of its catheter ablation technology and to further its technology development programs, including the ongoing clinical evaluation of its next-generation HeartLight® Excalibur Balloon™.
Led by Paul A. LaViolette, Executive Chairman, CardioFocus provides HeartLight® Endoscopic Ablation System, a catheter ablation technology designed for the treatment of atrial fibrillation (AF). The device received CE Mark in 2009 and U.S. FDA approval in April 2016. In addition the company is advancing the Excalibur Balloon, which leverages the universal balloon design of the HeartLight Endoscopic Ablation System and introduces an advanced feature set that optimizes the speed of target tissue contact during pulmonary vein isolation (PVI) procedures.
FinSMEs
29/03/2017